As part of an earlier inquiry in January 2021, the Taskforce told us how its portfolio strategy aimed to “optimise the chances of success” in securing access to vaccines at a time of huge uncertainty about whether effective vaccines were even feasible.42 The strategy worked well, giving the UK access to the earliest vaccines to complete clinical trials and come to market.43